Researchers believe combining navitoclax with ruxolitinib might help people with myelofibrosis. In this trial 50 percent the people have navitoclax and ruxolitinib. Another half have ruxolitinib and also a dummy drug (placebo ). The content posted in Cureus is the result of medical knowledge and/or exploration by unbiased persons or https://williame888qfq7.aboutyoublog.com/profile